Standard treatments for leukemia and myeloproliferative cancers include radiation therapy, chemotherapy, or both. Despite these therapies, the risk of the cancer coming back is high. Doctors are therefore seeking better treatments.
GSK525762 is an investigational drug that targets a family of proteins involved in leukemia growth called BET. It is hoped that targeting these proteins with GSK525762 can prevent leukemia cells from dividing.
The purpose of this study is to find the highest dose of GSK525762 that can be given safely in patients with leukemia and myeloproliferative cancers that continue to grow despite standard therapy. GSK525762 is taken orally (by mouth).